A randomized study, PROstate cancer follow-up care in Secondary and Primary hEalth Care (PROSPEC).

Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands0 sites390 target enrollmentTBD

ConditionsProstate cancer, survivorship, primary care, secondary care, follow-up, general practitioner, randomised controlled trialDutch: Prostaatcarcinoom, overlevingszorg, eerstelijnszorg, tweedelijnszorg, nazorg, huisarts, gerandomiseerd gecontroleerde trial.

Overview

Phase: N/A
Intervention: Not specified
Conditions: Prostate cancer, survivorship, primary care, secondary care, follow-up, general practitioner, randomised controlled trialDutch: Prostaatcarcinoom, overlevingszorg, eerstelijnszorg, tweedelijnszorg, nazorg, huisarts, gerandomiseerd gecontroleerde trial.
Sponsor: Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands
Enrollment: 390
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Investigators

Sponsor

Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands

Eligibility Criteria

Inclusion Criteria

•1\.Men diagnosed with invasive prostate cancer;
•2\.Stage cT1a–cT3; pNx–pN1; R0\-1 having completed primary treatment (prostatectomy or radiotherapy);

Exclusion Criteria

•1\.Primary treatment (prostatectomy, radiotherapy) not completed at least 3 months previously;
•2\.Patients under active surveillance;

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not Yet Recruiting

N/A

PROSPEC study; PROstate cancer follow-up care in Secondary and Primary hEalth Care

NL-OMON48798ederlands Kanker Instituut390

Unknown

N/A

Follow-up study for localized prostate cancer treated by hormonal therapy or radical prostatectomy.Prostate cancer

JPRN-UMIN000000570J-CaP study group2,000

Active, Not Recruiting

Phase 1

Study on patients with recurrence of prostate cancer with PET/MRRadically treated patient for prostate cancer presenting a biochemical recurrence of disease (PSA: > o = 0.2 ng/mL)MedDRA version: 21.1Level: LLTClassification code 10026389Term: Malignant neoplasm of prostateSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]

EUCTR2018-001036-21-ITOSPEDALE SAN RAFFAELE60

Active, Not Recruiting

N/A

Partial prostate Ablation versus Radical Treatment (PART): Comparing partial ablation of the prostate to treatment or removal of the whole prostate in men with localised cancer of one side of the prostate onlyProstate cancerCancer

ISRCTN17249875niversity of Oxford800

Recruiting

N/A

Clinical study of prostate cancer dagnositic makers using genetic polymorphismsProstate cancer

JPRN-UMIN000019278Kyoto University2,000